Cargando…

Class A and C GPCR Dimers in Neurodegenerative Diseases

Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Caniceiro, Ana B., Bueschbell, Beatriz, Schiedel, Anke C., Moreira, Irina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886835/
https://www.ncbi.nlm.nih.gov/pubmed/35339177
http://dx.doi.org/10.2174/1570159X20666220327221830
_version_ 1784880205326712832
author Caniceiro, Ana B.
Bueschbell, Beatriz
Schiedel, Anke C.
Moreira, Irina S.
author_facet Caniceiro, Ana B.
Bueschbell, Beatriz
Schiedel, Anke C.
Moreira, Irina S.
author_sort Caniceiro, Ana B.
collection PubMed
description Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G protein-coupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence.
format Online
Article
Text
id pubmed-9886835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-98868352023-04-27 Class A and C GPCR Dimers in Neurodegenerative Diseases Caniceiro, Ana B. Bueschbell, Beatriz Schiedel, Anke C. Moreira, Irina S. Curr Neuropharmacol Neurology Neurodegenerative diseases affect over 30 million people worldwide with an ascending trend. Most individuals suffering from these irreversible brain damages belong to the elderly population, with onset between 50 and 60 years. Although the pathophysiology of such diseases is partially known, it remains unclear upon which point a disease turns degenerative. Moreover, current therapeutics can treat some of the symptoms but often have severe side effects and become less effective in long-term treatment. For many neurodegenerative diseases, the involvement of G protein-coupled receptors (GPCRs), which are key players of neuronal transmission and plasticity, has become clearer and holds great promise in elucidating their biological mechanism. With this review, we introduce and summarize class A and class C GPCRs, known to form heterodimers or oligomers to increase their signalling repertoire. Additionally, the examples discussed here were shown to display relevant alterations in brain signalling and had already been associated with the pathophysiology of certain neurodegenerative diseases. Lastly, we classified the heterodimers into two categories of crosstalk, positive or negative, for which there is known evidence. Bentham Science Publishers 2022-10-27 2022-10-27 /pmc/articles/PMC9886835/ /pubmed/35339177 http://dx.doi.org/10.2174/1570159X20666220327221830 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Neurology
Caniceiro, Ana B.
Bueschbell, Beatriz
Schiedel, Anke C.
Moreira, Irina S.
Class A and C GPCR Dimers in Neurodegenerative Diseases
title Class A and C GPCR Dimers in Neurodegenerative Diseases
title_full Class A and C GPCR Dimers in Neurodegenerative Diseases
title_fullStr Class A and C GPCR Dimers in Neurodegenerative Diseases
title_full_unstemmed Class A and C GPCR Dimers in Neurodegenerative Diseases
title_short Class A and C GPCR Dimers in Neurodegenerative Diseases
title_sort class a and c gpcr dimers in neurodegenerative diseases
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886835/
https://www.ncbi.nlm.nih.gov/pubmed/35339177
http://dx.doi.org/10.2174/1570159X20666220327221830
work_keys_str_mv AT caniceiroanab classaandcgpcrdimersinneurodegenerativediseases
AT bueschbellbeatriz classaandcgpcrdimersinneurodegenerativediseases
AT schiedelankec classaandcgpcrdimersinneurodegenerativediseases
AT moreirairinas classaandcgpcrdimersinneurodegenerativediseases